Department of Emergency Care and Services, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Acta Anaesthesiol Scand. 2022 Aug;66(7):890-897. doi: 10.1111/aas.14090. Epub 2022 Jun 9.
Hypotension is common after cardiac arrest (CA), and current guidelines recommend using vasopressors to target mean arterial blood pressure (MAP) higher than 65 mmHg. Pilot trials have compared higher and lower MAP targets. We will review the evidence on whether higher MAP improves outcome after cardiac arrest.
This systematic review and meta-analysis will be conducted based on a systematic search of relevant major medical databases from their inception onwards, including MEDLINE, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL), as well as clinical trial registries. We will identify randomised controlled trials published in the English language that compare targeting a MAP higher than 65-70 mmHg in CA patients using vasopressors, inotropes and intravenous fluids. The data extraction will be performed separately by two authors (a third author will be involved in case of disagreement), followed by a bias assessment with the Cochrane Risk of Bias tool using an eight-step procedure for assessing if thresholds for clinical significance are crossed. The outcomes will be all-cause mortality, functional long-term outcomes and serious adverse events. We will contact the authors of the identified trials to request individual anonymised patient data to enable individual patient data meta-analysis, aggregate data meta-analyses, trial sequential analyses and multivariable regression, controlling for baseline characteristics. The certainty of the evidence will be assessed by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. We will register this systematic review with Prospero and aim to redo it when larger trials are published in the near future.
This protocol defines the performance of a systematic review on whether a higher MAP after cardiac arrest improves patient outcome. Repeating this systematic review including more data likely will allow for more certainty regarding the effect of the intervention and possible sub-groups differences.
心脏骤停(CA)后常发生低血压,目前的指南建议使用血管加压药将平均动脉压(MAP)目标值设定为高于 65mmHg。一些试点试验比较了较高和较低的 MAP 目标值。我们将回顾关于心脏骤停后较高的 MAP 是否改善预后的证据。
本系统评价和荟萃分析将基于对从开始起相关主要医学数据库的系统搜索,包括 MEDLINE、Embase 和 Cochrane 对照试验中心注册库(CENTRAL),以及临床试验注册库。我们将确定发表在英文期刊上的比较使用血管加压药、正性肌力药和静脉输液将 CA 患者的 MAP 目标值设定在高于 65-70mmHg 的随机对照试验。数据提取将由两名作者(如有分歧,将涉及第三名作者)分别进行,然后使用 Cochrane 偏倚风险工具进行偏倚评估,采用八步程序评估是否跨越临床意义的阈值。结局将是全因死亡率、长期功能结局和严重不良事件。我们将联系已确定试验的作者,要求提供个别匿名患者数据,以便进行个体患者数据荟萃分析、汇总数据荟萃分析、试验序贯分析和多变量回归,同时控制基线特征。证据的确定性将通过推荐、评估、开发和评估(GRADE)系统进行评估。我们将在 PROSPERO 上注册本系统评价,并计划在近期发表更大规模的试验后重新进行。
本方案定义了一项关于心脏骤停后较高的 MAP 是否改善患者预后的系统评价的执行情况。包括更多数据的重复系统评价可能会使干预效果和可能的亚组差异的确定性更高。